Avestar Capital LLC Acquires 257 Shares of Stryker Co. (NYSE:SYK)

Avestar Capital LLC boosted its holdings in shares of Stryker Co. (NYSE:SYK) by 8.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,205 shares of the medical technology company’s stock after purchasing an additional 257 shares during the period. Avestar Capital LLC’s holdings in Stryker were worth $1,154,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Dunhill Financial LLC boosted its stake in Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares in the last quarter. Darwin Wealth Management LLC bought a new position in shares of Stryker during the third quarter valued at $36,000. Activest Wealth Management acquired a new stake in shares of Stryker in the 4th quarter valued at $36,000. Crews Bank & Trust bought a new stake in shares of Stryker in the 4th quarter worth about $39,000. Finally, Hara Capital LLC acquired a new stake in shares of Stryker during the 3rd quarter worth about $42,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of Stryker stock opened at $385.49 on Thursday. The firm has a fifty day moving average of $377.19 and a two-hundred day moving average of $366.15. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock has a market capitalization of $146.96 billion, a price-to-earnings ratio of 49.68, a PEG ratio of 2.98 and a beta of 0.96. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the business earned $3.46 EPS. As a group, equities research analysts predict that Stryker Co. will post 13.49 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is currently 43.30%.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. StockNews.com lowered shares of Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, January 30th. BTIG Research boosted their target price on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Citigroup raised their price target on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Needham & Company LLC reissued a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research note on Wednesday, January 29th. Finally, Truist Financial increased their target price on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average target price of $420.68.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.